Actively Recruiting
Phase 12 Study of Acne mRNA Vaccine Safety and Effectiveness in Adults with Mild Acne Aged 18 to 45
Led by Sanofi Pasteur, a Sanofi Company · Updated on 2026-07-09
228
Participants Needed
4
Research Sites
38 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying an mRNA vaccine candidate for treating mild acne in adults aged 18 to 45 years. The study aims to evaluate the safety, immune response, and effectiveness of two doses of this vaccine. It includes a Core Study with a Sentinel Cohort for early safety assessment followed by a Main Cohort, and offers an optional Long-Term Extension to monitor long-term effects for up to 30 months after the Core Study. Participants will be randomly assigned to receive two injections of either the Acne mRNA vaccine or a placebo. The vaccine and placebo are given intramuscularly. The Core Study consists of a stepwise safety evaluation in the Sentinel Cohort and subsequent treatment in the Main Cohort. If participants agree to join, they can continue in the Long-Term Extension phase to observe safety and immune response over an extended period. During the study, participants will undergo medical evaluations including monitoring for adverse events, blood tests for immune response, and assessment of acne lesion changes on the face. Safety will be closely tracked immediately after doses, for days, and up to six months post-administration. The Long-Term Extension follows participants for serious adverse events and other safety outcomes up to 38 months after the first dose. The total participation duration includes both the Core Study and optional extended follow-up.
CONDITIONS
Brief Title
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here